upadacitinib

Upadacitinib is a highly selective Janus kinase 1 (JAK1) inhibitor developed as an oral small molecule therapy for the treatment of several autoimmune and inflammatory diseases. By selectively inhibiting JAK1, upadacitinib disrupts the JAK-STAT signaling pathway that mediates pro-inflammatory cytokine activity, thereby reducing inflammation and immune-mediated tissue damage. It is indicated for moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-axSpA), atopic dermatitis (eczema), ulcerative colitis, Crohn's disease, and polyarticular juvenile idiopathic arthritis in patients who have not responded adequately to other therapies[1][3][4][10]. Upadacitinib demonstrates greater selectivity for JAK1 over JAK2/3/TYK2 compared to earlier pan-JAK inhibitors[6][8]. It is available as extended-release tablets and oral solution formulations.

Brand names

Rinvoq瑞福锐虎

Other names

乌帕替尼